Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of NKTR-102 (PEG-irinotecan) in Metastatic or Locally Advanced Cervical Cancer (q14d vs q21d schedules)
2008-005578-12Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Apr 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of etirinotecan pegol in Cervical Cancer (CC) (2 arms), sponsored by Nektar Therapeutics. Primary endpoints: Objective response rate (ORR) – q14d schedule and Objective response rate (ORR) – q21d schedule. Started Apr 2009; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2008-005578-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005578-12.